Competition forcing marriage of iPads, ops data for execs

"We can't ignore any data telling us about the effectiveness of our business strategies," Pfizer ($PFE) VP for U.S. commercial ops David Kreutter told MIT Sloan Management Review. The stakes are too high for execs to eschew tablet PCs; "analytics has become much more operational than in the past," he said, echoing VP/GM Andy Amalfitano of Solarsoft Business Systems: "[The iPad] can be even more powerful in the hands of management, looking at every strategic advantage that could boost the bottom line. That's where manufacturing intelligence comes into play." Interview

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.